Article
Neurosciences
Soyeon Kim, Kiwon Kim, Kwangsik Nho, Woojae Myung, Hong-Hee Won
Summary: The study found a causal association between CSF biomarkers and the risk of LOAD, suggesting that the etiology of LOAD involves pathways of A beta and tau proteins. Further MR studies using large-scale data are needed to elucidate the pathophysiology of LOAD.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Review
Neurosciences
Donovan A. McGrowder, Fabian Miller, Kurt Vaz, Chukwuemeka Nwokocha, Cameil Wilson-Clarke, Melisa Anderson-Cross, Jabari Brown, Lennox Anderson-Jackson, Lowen Williams, Lyndon Latore, Rory Thompson, Ruby Alexander-Lindo
Summary: This review presents the current evidence on CSF biomarkers for Alzheimer's disease, emphasizing the efficacy of existing core biomarkers and the need for further development of biomarkers reflecting other aspects of the disease mechanism. It also introduces new biomarkers that track Alzheimer's disease pathology and their potential in diagnosis and predicting cognitive decline.
Article
Neurosciences
Qing Wang, Yachen Shi, Xinyang Qi, Lingyu Qi, Xiang Chen, Jingping Shi, Chunming Xie, Zhijun Zhang
Summary: This study found an association between platelet proteins and cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD). The platelet AβPP ratio was found to be a sensitive identifier for differentiating AD from non-AD pathologies. Additionally, phosphorylated tau levels were elevated in both AD and non-AD groups compared to normal controls.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Medical Laboratory Technology
Rosa Ferrer, Nuole Zhu, Javier Arranz, Inmaculada Porcel, Shaimaa El Bounasri, Oriol Sanchez, Soraya Torres, Josep Julve, Alberto Lleo, Francisco Blanco-Vaca, Daniel Alcolea, Mireia Tondo
Summary: This study aimed to investigate the potential influence of different storage conditions on the quantification of biomarkers related to Alzheimer's disease in cerebrospinal fluid. The results showed that temperature and storage days significantly impacted the concentrations of certain biomarkers. However, the use of a ratio between two biomarkers could partially compensate for this influence. Other biomarkers were not affected by the tested storage conditions. The findings suggest that specific correction factors can be applied for samples stored at 4 degrees C.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Ioanna Tsantzali, Fotini Boufidou, Eleni Sideri, Antonis Mavromatos, Myrto G. Papaioannou, Aikaterini Foska, Ioannis Tollos, Sotirios G. Paraskevas, Anastasios Bonakis, Konstantinos I. Voumvourakis, Georgios Tsivgoulis, Elisabeth Kapaki, George P. Paraskevas
Summary: Analysis of classical cerebrospinal fluid biomarkers, especially in the context of a diagnostic system like AT(N), can be a significant tool for diagnosing Alzheimer's disease accurately during a patient's lifetime. Despite atypical clinical presentations, the classical biomarker profile was consistent with Alzheimer's disease in four patients, demonstrating the potential usefulness of these biomarkers for identifying the biochemical fingerprints of the disease.
Article
Immunology
Kaja Nordengen, Bjorn-Eivind Kirsebom, Grit Richter, Lene Palhaugen, Berglind Gisladottir, Nikias Siafarikas, Arne Nakling, Arvid Rongve, Geir Brathen, Goril Rolfseng Grontvedt, Fernando Gonzalez, Knut Waterloo, Kulbhushan Sharma, Thomas Karikari, Eleonora M. Vromen, Betty M. Tijms, Pieter J. Visser, Per Selnes, Milicia G. Kramberger, Bengt Winblad, Kaj Blennow, Tormod Fladby
Summary: Brain innate immune activation is associated with Alzheimer's disease, with varying degrees of activation at different disease stages. In predementia AD, differences in immune activation levels and biomarker profiles may be related to amyloidosis and tau pathology. Changes in certain biomarkers in cerebrospinal fluid may be linked to cognitive preservation or impairment in predementia AD.
JOURNAL OF NEUROINFLAMMATION
(2023)
Article
Neurosciences
Feifei Ge, Lin Dong, Donglin Zhu, Xingjian Lin, Jingping Shi, Ming Xiao
Summary: Thyroid dysfunction has been implicated in the pathogenesis of Alzheimer's disease (AD). This study found that even in euthyroid subjects, low levels of serum FT3 and TT3 are differentially associated with AD-specific CSF changes. Serum FT3 is a strong candidate for the differential diagnosis between AD continuum and non-AD dementia, benefiting the early diagnosis and effective management of AD patients.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Stefanos N. Sampatakakis, Eirini Mamalaki, Eva Ntanasi, Faidra Kalligerou, Ioannis Liampas, Mary Yannakoulia, Antonios N. Gargalionis, Nikolaos Scarmeas
Summary: Cognitive and physical decline in aging individuals seem to be associated. This study investigated the relationship between physical function parameters and CSF biomarkers in individuals in the AD continuum. The findings suggest an inverse association between walking time and CSF A beta 42, particularly in individuals with MCI and those older than 60 years old.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Yuetiva Deming, Eva Vasiljevic, Autumn Morrow, Jiacheng Miao, Carol Van Hulle, Erin Jonaitis, Yue Ma, Vanessa Whitenack, Gwendlyn Kollmorgen, Norbert Wild, Ivonne Suridjan, Leslie M. Shaw, Sanjay Asthana, Cynthia M. Carlsson, Sterling C. Johnson, Henrik Zetterberg, Kaj Blennow, Barbara B. Bendlin, Qiongshi Lu, Corinne D. Engelman
Summary: APOE epsilon 4-carrier status and epsilon 4 allele count are not sufficient to fully account for the effects of APOE on Alzheimer's disease. A weighted risk score (APOE-npscore) was developed to better explain the genetic effect on neuropathology and provide an improved method for analyzing APOE in relation to AD. This approach outperformed the traditional APOE epsilon 4-carrier status and epsilon 4 allele count in predicting CSF biomarker changes.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Anna M. De Kort, H. Bea Kuiperij, Daniel Alcolea, Iris Kersten, Alexandra A. M. Versleijen, Steven M. Greenberg, Erik Stoops, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Alberto Lleo, Jurgen A. H. R. Claassen, Marcel M. Verbeek
Summary: Our study found that CSF NLK levels are elevated in aMCI and AD patients compared to controls, but did not increase in CAA patients. Furthermore, we observed a correlation of CSF NLK with CSF YKL-40 in aMCI/AD patients.
ALZHEIMERS RESEARCH & THERAPY
(2021)
Article
Neurosciences
Emma van den Berg, Johanna Nilsson, Iris Kersten, Gunnar Brinkmalm, Anna M. de Kort, Catharina J. M. Klijn, Floris H. B. M. Schreuder, Lieke Jakel, Johan Gobom, Erik Portelius, Henrik Zetterberg, Ann Brinkmalm, Kaj Blennow, H. Bea Kuiperij, Marcel M. Verbeek
Summary: This study investigated synaptic dysfunction in cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). The results showed that synaptic protein levels were largely unchanged in CAA patients, while they were significantly increased in AD patients. It was also found that abnormal synaptic protein levels were associated with concomitant AD pathology in CAA patients. These findings suggest a differential involvement of synaptic dysfunction in CAA and AD, possibly reflecting distinct pathological mechanisms.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Clinical Neurology
Katherine W. Turk, Alexandra Geada, Victor E. Alvarez, Weiming Xia, Jonathan D. Cherry, Raymond Nicks, Gaoyuan Meng, Sarah Daley, Yorghos Tripodis, Bertrand R. Huber, Andrew E. Budson, Brigid Dwyer, Neil W. Kowall, Robert C. Cantu, Lee E. Goldstein, Douglas I. Katz, Robert A. Stern, Michael L. Alosco, Jesse Mez, Ann C. McKee, Thor D. Stein
Summary: CSF levels of p-tau(231) were higher in CTE patients, indicating it may be a potential biomarker for CTE diagnosis. Additionally, A beta(1-42) levels were lower in CTE patients, suggesting further investigation is needed for its role in CTE. The study highlights the differences in CSF analytes between CTE and AD patients.
ALZHEIMERS RESEARCH & THERAPY
(2022)
Article
Clinical Neurology
Sterling C. Johnson, Marc Suarez-Calvet, Ivonne Suridjan, Carolina Minguillon, Juan Domingo Gispert, Erin Jonaitis, Agata Michna, Margherita Carboni, Tobias Bittner, Christina Rabe, Gwendlyn Kollmorgen, Henrik Zetterberg, Kaj Blennow
Summary: This study compared cerebrospinal fluid biomarker results across different cohorts, and found that after correction, the distributions and correlations of biomarkers were comparable. The relationship between biomarker concentration and cognitive scores was also similar. Assessing multiple cohorts is crucial in increasing power for future studies on Alzheimer's disease pathogenesis.
ALZHEIMERS RESEARCH & THERAPY
(2023)
Editorial Material
Neurosciences
Allyson C. Rosen, Jalayne J. Arias, J. Wesson Ashford, Deborah Blacker, Jasmeer P. Chhatwal, Nathan A. Chin, Lindsay Clark, Sharon S. Denny, Jill S. Goldman, Carey E. Gleason, Joshua D. Grill, Judith L. Heidebrink, Victor W. Henderson, James A. Lavacot, Jennifer H. Lingler, Malavika Menon, Rachel L. Nosheny, Fabricio F. Oliveira, Monica W. Parker, Annalise Rahman-Filipiak, Anwita Revoori, Malia C. Rumbaugh, Danurys L. Sanchez, Suzanne E. Schindler, Christopher G. Schwarz, Leslie Toy, Jamie Tyrone, Sarah Walter, Li-San Wang, Ellen M. Wijsman, Doris T. Zallen, Neelum T. Aggarwala
Summary: The public is increasingly recognizing the value of accessing dementia risk evidence (DRE) as it can guide diagnosis and clinical management, while researchers are considering how to share and use this evidence.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Clinical Neurology
Matilde Nerattini, Federica Rubino, Annachiara Arnone, Cristina Polito, Salvatore Mazzeo, Gemma Lombardi, Giulia Puccini, Benedetta Nacmias, Maria Teresa De Cristofaro, Sandro Sorbi, Alberto Pupi, Roberto Sciagra, Valentina Bessi, Valentina Berti
Summary: The study aims to interpret discrepancies between amyloid PET and CSF biomarkers in Alzheimer's disease diagnosis, utilizing a combination of different imaging and biomarker analysis techniques to improve diagnostic accuracy.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Anders Wimo, Ron Handels, Riitta Antikainen, Maria Eriksdotter, Linus Jonsson, Martin Knapp, Jenni Kulmala, Tiina Laatikainen, Jenni Lehtisalo, Markku Peltonen, Anders Skoldunger, Hilkka Soininen, Alina Solomon, Timo Strandberg, Jaakko Tuomilehto, Tiia Ngandu, Miia Kivipelto
Summary: This study estimated the potential cost-effectiveness of the FINGER program in Finland. The results showed that the FINGER program could save costs and improve quality-adjusted life years, supporting its effectiveness in preventing cognitive impairment and disability.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Milan Nemy, Martin Dyrba, Frederic Brosseron, Katharina Buerger, Peter Dechent, Laura Dobisch, Michael Ewers, Klaus Fliessbach, Wenzel Glanz, Doreen Goerss, Michael T. Heneka, Stefan Hetzer, Enise I. Incesoy, Daniel Janowitz, Ingo Kilimann, Christoph Laske, Franziska Maier, Matthias H. Munk, Robert Perneczky, Oliver Peters, Lukas Preis, Josef Priller, Boris-Stephan Rauchmann, Sandra Roeske, Nina Roy, Klaus Scheffler, Anja Schneider, Bjorn H. Schott, Annika Spottke, Eike J. Spruth, Michael Wagner, Jens Wiltfang, Renat Yakupov, Maria Eriksdotter, Eric Westman, Olga Stepankova, Lenka Vyslouzilova, Emrah Duezel, Frank Jessen, Stefan J. Teipel, Daniel Ferreira
Summary: Nemy et al. investigate cholinergic white matter projections along the Alzheimer's disease continuum, finding that alterations in these pathways are present in individuals with subjective cognitive decline. These alterations precede the more widespread changes seen in mild cognitive impairment and Alzheimer's disease dementia. The study highlights the potential of using cholinergic white matter pathways as markers for the early stages of Alzheimer's disease.
Article
Urology & Nephrology
Hong Xu, Sara Garcia-Ptacek, Annette Bruchfeld, Edouard L. Fu, Taher Darreh Shori, Bengt Lindholm, Maria Eriksdotter, Juan Jesus Carrero
Summary: Preclinical evidence suggests that the use of Cholinesterase inhibitors (ChEIs) may have beneficial effects on the kidney. This study examined the risk of chronic kidney disease (CKD) progression among newly diagnosed Alzheimer's disease (AD) patients who either used or did not use ChEIs. The results showed that ChEI use was associated with a lower risk of CKD progression.
KIDNEY INTERNATIONAL
(2023)
Article
Clinical Neurology
Yang Yang, Wenjuan Zhang, Alexey G. Murzin, Manuel Schweighauser, Melissa Huang, Sofia Lovestam, Sew Y. Peak-Chew, Takashi Saito, Takaomi C. Saido, Jennifer Macdonald, Isabelle Lavenir, Bernardino Ghetti, Caroline Graff, Amit Kumar, Agneta Nordberg, Michel Goedert, Sjors H. W. Scheres
Summary: The high-resolution cryo-EM structures of A beta filaments with the Arctic mutation were reported in this study. Most of the filaments consist of two pairs of non-identical protofilaments, sharing a common substructure with the folds of type I and type II A beta 42. There are subtle conformational changes in the human Arctic folds, which may be due to the lack of a side chain at G22.
ACTA NEUROPATHOLOGICA
(2023)
Article
Dentistry, Oral Surgery & Medicine
Anton Jonsson, Jacob Holmer, Leif Kullman, Maria Eriksdotter, Jan Ahlqvist, Eva Levring Jaeghagen, Kare Buhlin
Summary: In this middle-aged and older Swedish population, CCAA was found to be common (40%). There were no differences in the prevalence of CCAA between cases with cognitive impairment and controls without cognitive impairment.
ACTA ODONTOLOGICA SCANDINAVICA
(2023)
Article
Clinical Neurology
David J. Whiteside, Maura Malpetti, P. Simon Jones, Boyd C. P. Ghosh, Ian Coyle-Gilchrist, John C. van Swieten, Harro Seelaar, Lize Jiskoot, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Caroline Graff, Matthis Synofzik, Daniela Galimberti, Mario Masellis, Maria Carmela Tartaglia, Elizabeth Finger, Rik Vandenberghe, Alexandre de Mendonca, Fabrizio Tagliavini, Chris R. Butler, Isabel Santana, Isabelle Le Ber, Alexander Gerhard, Simon Ducharme, Johannes Levin, Adrian Danek, Markus Otto, Sandro Sorbi, Florence Pasquier, Arabella Bouzigues, Lucy L. Russell, Jonathan D. Rohrer, James B. Rowe, Timothy Rittman
Summary: This study investigated the role of changes in functional networks in predicting cognitive decline and conversion to symptomatic disease in familial frontotemporal dementia (FTD). The study found a characteristic pattern of dynamic network changes in FTD, which were correlated with neuropsychological impairment. Among presymptomatic mutation carriers, this pattern of network dynamics was more prominent in those who later converted to the symptomatic phase. Baseline network dynamic changes predicted future cognitive decline in symptomatic participants and older presymptomatic participants.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Elizabeth Finger, Rubina Malik, Martina Bocchetta, Kristy Coleman, Caroline Graff, Barbara Borroni, Mario Masellis, Robert Laforce, Caroline Greaves, Lucy L. Russell, Rhian S. Convery, Arabella Bouzigues, David M. Cash, Markus Otto, Matthis Synofzik, James B. Rowe, Daniela Galimberti, Pietro Tiraboschi, Robert Bartha, Christen Shoesmith, Maria Carmela Tartaglia, John C. van Swieten, Harro Seelaar, Lize C. Jiskoot, Sandro Sorbi, Chris R. Butler, Alexander Gerhard, Raquel Sanchez-Valle, Alexandre de Mendonca, Fermin Moreno, Rik Vandenberghe, Isabelle Le Ber, Johannes Levin, Florence Pasquier, Isabel Santana, Jonathan D. Rohrer, Simon Ducharme
Summary: This study investigates the hypothesis that genetic mutations causing frontotemporal dementia (FTD) have neurodevelopmental consequences. The researchers examined brain structure and function in young adult mutation carriers and found differences between preclinical mutation carriers and familial non-carriers at a mean age of 26 years. These findings have implications for therapeutic interventions and further studies on early pathophysiologic processes in FTD.
Article
Clinical Neurology
Charlotte Johansson, Steinunn Thordardottir, Jose Laffita-Mesa, Elena Rodriguez-Vieitez, Henrik Zetterberg, Kaj Blennow, Caroline Graff
Summary: The study describes plasma biomarkers in a Swedish cohort of patients with monogenic Alzheimer's disease. Plasma GFAP increases before P-tau181 and NfL, indicating that it reflects early Alzheimer's disease pathology. Plasma biomarkers may be non-invasive tools to detect Alzheimer's disease-related abnormalities. However, further validation is needed.
Article
Geriatrics & Gerontology
Jonathan K. L. Mak, Maria Eriksdotter, Martin Annetorp, Ralf Kuja-Halkola, Laura Kananen, Anne-Marie Bostrom, Miia Kivipelto, Carina Metzner, Viktoria Back Jerlardtz, Malin Engstrom, Peter Johnson, Lars Goran Lundberg, Elisabet Akesson, Carina Suhl Oberg, Maria Olsson, Tommy Cederholm, Sara Hagg, Dorota Religa, Juulia Jylhava
Summary: This retrospective cohort study used electronic health records to investigate the association between frailty and outcomes in older COVID-19 patients. The results showed that a medical record-based electronic frailty index (eFI) was effective for risk stratification in hospitalized COVID-19 patients. Frailty was significantly associated with higher mortality, readmission, and longer hospital stays, and the eFI had the best predictive accuracy among all measures.
Article
Clinical Neurology
Kiran Samra, Amy M. MacDougall, Arabella Bouzigues, Martina Bocchetta, David M. Cash, Caroline Greaves, Rhian S. Convery, John C. van Swieten, Harro Seelaar, Lize Jiskoot, Fermin Moreno, Raquel Sanchez-Valle, Robert Laforce, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B. Rowe, Barbara Borroni, Elizabeth Finger, Matthis Synofzik, Daniela Galimberti, Rik Vandenberghe, Alexandre de Mendonca, Christopher R. Butler, Alexander Gerhard, Simon Ducharme, Isabelle Le Ber, Pietro Tiraboschi, Isabel Santana, Florence Pasquier, Johannes Levin, Markus Otto, Sandro Sorbi, Jonathan D. Rohrer, Lucy L. Russell
Summary: The study found that about 76% of patients with genetic bvFTD have language impairments, characterized by impaired functional communication, decreased fluency, and impaired sentence comprehension. There are differences in the extent of brain atrophy in specific language regions and language symptoms among different genetic types of patients. This research is helpful for further understanding the language phenotype associated with genetic bvFTD, especially in accurate stratification and monitoring of disease progression in clinical trials.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Kiran Samra, Amy M. MacDougall, Arabella Bouzigues, Martina Bocchetta, David M. Cash, Caroline Greaves, Rhian S. Convery, Chris Hardy, John C. van Swieten, Harro Seelaar, Lize C. Jiskoot, Fermin Moreno, Raquel Sanchez-Valle, Robert Laforce, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B. Rowe, Barbara Borroni, Elizabeth Finger, Matthis Synofzik, Daniela Galimberti, Rik Vandenberghe, Alexandre de Mendonca, Chris R. Butler, Alexander Gerhard, Simon Ducharme, Isabelle Le Ber, Isabel Santana, Florence Pasquier, Johannes Levin, Markus Otto, Sandro Sorbi, Jason D. Warren, Jonathan D. Rohrer, Lucy L. Russell
Summary: Samra et al. report that progranulin mutations are the most common genetic cause of primary progressive aphasia, with two subtypes observed. Revised criteria for primary progressive aphasia should take into account genetic phenotypes. Primary progressive aphasia is typically sporadic, but can also be genetic.
BRAIN COMMUNICATIONS
(2023)
Article
Clinical Neurology
Martina Bocchetta, Emily G. Todd, Arabella Bouzigues, David M. Cash, Jennifer M. Nicholas, Rhian S. Convery, Lucy L. Russell, David L. Thomas, Ian B. Malone, Juan Eugenio Iglesias, John C. van Swieten, Lize C. Jiskoot, Harro Seelaar, Barbara Borroni, Daniela Galimberti, Raquel Sanchez-Valle, Robert Laforce, Fermin Moreno, Matthis Synofzik, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B. Rowe, Rik Vandenberghe, Elizabeth Finger, Fabrizio Tagliavini, Alexandre de Mendonca, Isabel Santana, Chris R. Butler, Simon Ducharme, Alexander Gerhard, Adrian Danek, Johannes Levin, Markus Otto, Sandro Sorbi, Isabelle Le Ber, Florence Pasquier, Jonathan D. Rohrer
Summary: The study quantified brain anomalies on MRI in individuals with C9orf72, MAPT, and GRN mutations. The identified imaging markers associated with clinical and behavioral changes in presymptomatic carriers over one year, providing important data for participant stratification in trials. Biomarkers predicting disease progression in genetic frontotemporal dementia are urgently needed.
BRAIN COMMUNICATIONS
(2023)
Meeting Abstract
Biochemistry & Molecular Biology
Emma Ehn, Jesper Eisfeldt, Hakan Thonberg, Jose Laffita, Jacqueline Schoumans, Anne Remes, Matti Viitanen, Anna Lindstrand, Inger Nennesemo, Caroline Graff
EUROPEAN JOURNAL OF HUMAN GENETICS
(2023)
Meeting Abstract
Clinical Neurology
S. Schoenecker, F. J. Martinez-Murcia, N. Franzmeier, J. Denecke, A. Bernhard, O. Wagemann, E. Wlasich, G. U. Hoeglinger, J. C. Van Swieten, F. Moreno, M. Otto, R. Laforce, C. Graff, M. Masellis, M. Carmela Tartaglia, J. B. Rowe, B. Borroni, E. Finger, M. Synofzik, D. Galimberti, R. Vandenberghe, A. De Mendonca, S. Ducharme, J. D. Rohrer, J. Levin
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Meeting Abstract
Clinical Neurology
Giancarlo Logroscino, Marco Piccininni, Caroline Graff, Orla Hardiman, Albert Ludolph, Fermin Moreno, Markus Otto, Anne Remes, James Rowe, Harro Seelaar, Eino Solje, Elka Stefanova, Latchezar Traykov, Vesna Jelic, Melissa Thaeri Rydell, Niall Pender, Sarah Anderl-Straub, Myriam Barandiaran, Alazne Gabilondo, Johanna Kruger, Alexander Murley, Timothy Rittman, Emma L. Van der Ende, John Van Swieten, Paivi Hartikainen, Gorana Mandic Stojmenovic, Shima Meherabian, Luisa Benussi, Antonella Alberici, Maria Teresa Dell'Abate, Chiara Zecca, Barbara Borroni